Download Our laboratory has been particularly interested in mechanisms of

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Endomembrane system wikipedia , lookup

Gene regulatory network wikipedia , lookup

History of molecular evolution wikipedia , lookup

Biochemistry wikipedia , lookup

Cell culture wikipedia , lookup

Signal transduction wikipedia , lookup

Synthetic biology wikipedia , lookup

Cell-penetrating peptide wikipedia , lookup

Gene therapy of the human retina wikipedia , lookup

List of types of proteins wikipedia , lookup

Transcript
Offer of
Post-doctoral fellowship in vision science / cell biology
Candidate eligibility:
PhD in cell biology, biochemistry or molecular biology
Minimal technical requirements:
Molecular and cellular biology
Immunohistochemistry
Animal handling/experimentation (desirable)
Host laboratory environment:
- Established laboratory in vision science, pharmacology and cell physiology.
- Well-versed laboratory in technology transfer.
- Laboratory composition: 4 research associates, 2 post-doctoral fellows, 6 PhD
students.
- Research group: Vascular biology and age-related macular degeneration (AMD).
- Research Center fully equipped for vision science at Hôpital Maisonneuve-Rosemont.
Project:
Title: Characterization of novel proprietary CD36 modulators in models of age-related
macular degeneration.
The post-doc position is both academic and industrial (Mperia Therapeutics - a newly
launched biotech). CD36 is a scavenger receptor localized on endothelial cells,
macrophage/microglia and on retinal pigment epithelium, all three cell types affected in
AMD. Our proprietary CD36 modulators protect the sub-retina in models of AMD.
General objective: Optimization of CD36 modulators is essential to better understand
structure-activity relationship; cell biological mechanism of action of these molecules is
also critical to elucidate new drug candidates, including through cellular interactions.
Findings will provide breakthrough therapeutics especially for ‘dry’ form AMD, for
which there is currently no treatment.
Contact information:
Sylvain Chemtob, MD, PhD, FRCPC, FCAHS
Professor of Ophthalmology, Pediatrics and Pharmacology, Université de Montréal
Departments of Ophthalmology, Pediatrics, Centre Hospitalier Universitaire Ste Justine
Email: [email protected] or [email protected]
Tel: 514-585-4604